A decision is a beginning. What happens next?

A proposed service may need training, appointment capacity, referral routes, stock, documentation and a way to resolve exceptions. Any one of these can become the limiting factor. We want to examine a defined medicines change from agreement to delivery, following the handovers rather than treating the announcement as implementation. The research question is where progress becomes difficult, who experiences that difficulty and what can realistically remove it.

We propose tracing a small set of observable stages appropriate to the service, such as eligible opportunities, referrals received, actions attempted and actions completed. The exact definitions would be agreed locally. A rise in one stage should not be mistaken for success across the whole pathway. Reasons for non-completion, repeated attempts and staff workarounds would be examined with enough context to understand the pattern without exposing personal information unnecessarily.

A phased introduction, matched setting or carefully documented baseline may provide a useful comparator, depending on the circumstances. Staffing changes, seasonal pressures and parallel initiatives could alter the result independently of the proposed support. Our design would make those influences visible. The purpose is to investigate an explanation for what changed, not simply place a before-and-after line on a chart and attribute the difference to PHARMORIS.

The Magenta Book offers evaluation context, while HRA guidance distinguishes public involvement from participation in a study (HM Treasury, n.d.; Health Research Authority, n.d.). Where the proposed work affects people receiving care, their perspectives should inform suitable questions and acceptable methods. Classification, permissions and governance would be established for the actual project. We are inviting discussion of an evaluation design, not announcing an approved study or a result across healthcare settings.

A first proposal would focus on one change, one accountable owner and a limited observation period agreed around the service. Expansion would depend on credible evidence of useful follow-through without an unacceptable increase in burden or risk. We would pause if the service cannot supply a trustworthy baseline, if responsibilities remain unresolved or if the proposed support merely moves work to another team. The result should tell a partner what to do differently.

For example, a referral pathway might generate more incoming work while the receiving team lacks capacity to complete it. Mapping that bottleneck would change the proposed intervention: clearer referral messaging alone may be insufficient. The study should help the owner decide whether to adjust capacity, eligibility, coordination or the original plan before seeking wider adoption.